Research progress of three antiangiogenic agents in the treatment of advanced colorectal cancer

Abstract

Abstract:Angiogenesis plays a vital role in carcinogenesis and development of colorectal cancer. Treatment targeting VEGF signaling pathway acquires important survival prolong for advanced colorectal cancer patients. For advanced colorectal cancer patients, bevacizumab could furtherly prolongs survival time in the setting of first line, second line and continuing therapy after firstprogression therapy combined with chemotherapy. Aflibercept used in combination with irinotecancontaining regimen improves the survival of advanced colorectal cancer patients in secondline setting. Regorafenib also improves the survival of advanced colorectal cancer patients who have progressed after all line treatment. Considering these suivival benefit and their favorable safety, antiangiogenic agents should be taken into all lines of therapy in the management of advanced colorectal cancer.

Key words:Angiogenesis inhibitors,Colorectal neoplasms,Aflibercept,Regorafenib

WU Zheng-Qi-；Zhang-Zhi-Yi-；Wang-Hui-Juan-；Liu-Xiao-Jun. Research progress of three antiangiogenic agents in the treatment of advanced colorectal cancer[J]. Journal of International Oncology, 2015, 42(4): 301-304.

References

［1］ DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014［J］. CA Cancer J Clin, 2014, 64(4): 252271. ［2］蔡浩权, 林英城. 不可切除转移性结直肠癌的治疗策略［J］. 国际肿瘤学杂志, 2012, 39(10): 775778. ［3］ Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as firstline treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE Study［J］. J Clin Oncol, 2006, 24(21): 35233529. ［4］ Saltz LB, Clarke S, DíazRubio E, et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase Ⅲ study［J］. J Clin Oncol, 2008, 26(12): 20132019. ［5］ Park MS, Ravi V, Araujo DM. Inhibiting the VEGFVEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor［J］. Curr Opin Oncol, 22(4): 351355. ［6］ Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis a crucial target for antiand proangiogenic therapies［J］. Genes Cancer, 2011, 2(12): 10971105. ［7］ Saif MW. AntiVEGF agents in metastatic colorectal cancer (mCRC): are they all alike?［J］. Cancer Manag Res, 2013, 5: 103115. ［8］ Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy［J］. Biol Pharm Bull, 2011, 34(12): 17851788. ［9］ Eichten A, Adler AP, Cooper B, et al. Rapid decrease in tumor perfusion following VEGF blockade predicts longterm tumor growth inhibition in preclinical tumor models［J］. Angiogenesis, 2013, 16(2): 429441. ［10］刘小军, 周永宁, 赵达. 贝伐单抗治疗恶性肿瘤不良反应的策略［J］. 国际肿瘤学杂志, 2011, 38(9): 711714. ［11］ de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial［J］. Lancet Oncol, 2012, 13(12): 12251233. ［12］ Clarke JM, Hurwitz HI. Targeted therapies: Zivaflibercept: binding to more than VEGFA—does more matter?［J］. Nat Rev Clin Oncol, 2013, 10(1): 1011. ［13］ Dietvorst MH, Eskens FA. Current and novel treatment options for metastatic colorectal cancer: emphasis on aflibercept［J］. Biol Ther, 2013, 3: 2533. ［14］ Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept［J］. Clin Colorectal Cancer, 2013, 12(2): 7385. ［15］ Ciombor KK, Berlin J. Aflibercept—a decoy VEGF receptor［J］. Curr Oncol Rep, 2014, 16(2): 17. ［16］ Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase Ⅲ randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen［J］. J Clin Oncol, 2012, 30(28): 34993506. ［17］ He K, Cui B, Li G, et al. The effect of antiVEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)［J］. Onco Targets Ther, 2012, 5: 5965. ［18］ Lockhart AC, Rothenberg ML, Dupont J, et al. Phase Ⅰ study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors［J］. J Clin Oncol, 2010, 28(2): 207214. ［19］ Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer［J］. Cancer Treat Rev, 2012, 38(5): 484493. ［20］ Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 734506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity［J］. Int J Cancer, 2011, 129(1): 245255. ［21］ Azad N, Dasari A, Arcaroli J, et al. Phase Ⅰ pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer［J］. Invest New Drugs, 2013, 31(2): 345354. ［22］ Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase Ⅰ study with the combination irinotecan and sorafenib［J］. Eur J Cancer, 2007, 43(1): 5563. ［23］ Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 734506) in advanced colorectal cancer: a phase Ⅰ study［J］. Br J Cancer, 2012, 106(11): 17221727. ［24］ SartoreBianchi A, Zeppellini A, Amatu A, et al. Regorafenib in metastatic colorectal cancer［J］. Expert Rev Anticancer Ther, 2014, 14(3): 255265. ［25］ Mross K, Frost A, Steinbild S, et al. A Phase Ⅰ doseescalation study of regorafenib (BAY 734506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors［J］. Clin Cancer Res, 2012, 18(9): 26582667. ［26］ Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib［J］. J Gastrointest Oncol, 2013, 4(2): 231238. ［27］ Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863): 303312.

[1]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang.Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang.Predictive value of inflammatory markers in colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong.Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer[J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu.Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment[J]. Journal of International Oncology, 2022, 49(8): 490-493.